The estimated Net Worth of Gary C Evans is at least $13.8 Million dollars as of 19 January 2023. Mr. Evans owns over 21,368 units of Novavax stock worth over $11,759,674 and over the last 21 years he sold NVAX stock worth over $1,927,392. In addition, he makes $121,796 as Independent Director at Novavax.
Gary has made over 36 trades of the Novavax stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 21,368 units of NVAX stock worth $9,616 on 19 January 2023.
The largest trade he's ever made was selling 691,376 units of Novavax stock on 22 June 2011 worth over $850,392. On average, Gary trades about 51,147 units every 112 days since 2003. As of 19 January 2023 he still owns at least 956,849 units of Novavax stock.
You can see the complete history of Mr. Evans stock trades at the bottom of the page.
Gary C. Evans is an Independent Director of Novavax, Inc. Mr. Evans is Chairman of the Board and Chief Executive Officer of Generation Hemp, Inc. since 2019, and prior to that Chairman of the Board and Chief Executive Officer of Energy Hunter Resources, Inc., a Dallas based oil and gas exploration and production company, from May 2016 to November 2019. From May 2009 until May 2016, Mr. Evans served as Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources Corporation (“Magnum Hunter”). In December 2015, Magnum Hunter filed for Chapter 11 bankruptcy and exited restructuring in May 2016 under Mr. Evans’ leadership. Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, Magnum Hunter Resources Inc., Wind Hunter Energy, LLC, and GreenHunter Energy, Inc. Mr. Evans was inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. He was also recognized as the Energy Industry Leader of the year in 2013 and chosen by Finance Monthly in 2013 as one of the most respected CEO’s. Mr. Evans was chosen as the Best CEO in the “Large Company” category by Texas Top Producers in 2013 and won the Deal Maker of the Year Award in 2013 by Finance Monthly. Mr. Evans serves as a member of the board of directors of Generation Hemp, Inc., and on the Advisory Board of the Maguire Energy Institute at Southern Methodist University.
As the Independent Director of Novavax, the total compensation of Gary Evans at Novavax is $121,796. There are 10 executives at Novavax getting paid more, with Stanley Erck having the highest compensation of $2,438,560.
Gary Evans is 62, he's been the Independent Director of Novavax since 2011. There are 9 older and 13 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
Gary's mailing address filed with the SEC is 47 COX GULCH RD., , THOMPSON FALLS, MN, 56873.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: